Rare diseases often face significant challenges in drug discovery and development, including limited patient populations, fragmented data, and high research costs. A recent editorial in Drug Discovery Today highlights the potential of precompetitive collaboration to address some of these challenges.
The Value of Collaboration
Precompetitive partnerships can bring together researchers, pharmaceutical companies, clinicians, patient organisations, and other stakeholders to share knowledge and resources. By collaborating in areas where organisations face common scientific challenges, stakeholders can help reduce duplication and accelerate progress across the rare disease research landscape.
The article highlights how stronger collaboration across the rare disease ecosystem could help overcome some of the persistent barriers to drug discovery and development. By bringing together all the stakeholders involved in the process, precompetitive initiatives can support the sharing of knowledge, expertise, data, and research resources. Ultimately, greater collaboration could contribute to accelerating the development of new therapeutic options and ensuring that advances in rare disease research translate into meaningful benefits for patients and their families.
Read the full editorial: https://www.sciencedirect.com/science/article/pii/S1359644626002047?via%3Dihub
We extend our appreciation to the IRDiRC members and collaborators who contributed to the development of this article.